Metformin Temporal and Localized Effects on Gut Glucose Metabolism Assessed Using 18F-FDG PET in Mice
- 3 January 2013
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 54 (2), 259-266
- https://doi.org/10.2967/jnumed.112.106666
Abstract
In the course of metformin treatment, staging abdominal cancer lesions with 18F-FDG PET images is often hindered by the presence of a high bowel radioactivity. The present study aimed to verify the mechanism underlying this phenomenon. Methods: Fifty-three mice were submitted to dynamic acquisitions of 18F-FDG kinetics under fasting conditions. Three small-animal PET scans were obtained over a 4-mo study period. The animals were subdivided into 4 groups according to the following metformin administration protocol: group 1, untreated mice (n = 15); group 2, mice exposed to metformin treatment (750 mg/kg/d) for the 48 h before each PET study (pulsed, n = 10); group 3, mice treated for the whole study period (prolonged, n = 10); and group 4, mice in which prolonged treatment was interrupted 48 h before PET (interrupted, n = 8). The rate constant of 18F-FDG uptake was estimated by Patlak analysis. At the end of the study, the ileum and colon were harvested, washed, and counted ex vivo. Two further groups, of 5 animals each, were included to evaluate the effect of prolonged metformin treatment on phosphorylated adenosine monophosphate (AMP)–activated protein kinase (pAMPK) form and gene expression for thioredoxin-interacting protein (TXNIP). Results: Pulsed treatment did not modify gut tracer retention with respect to the untreated group. Conversely, prolonged treatment induced a progressive increase in 18F-FDG uptake that selectively involved the colonic wall, without any significant contamination of bowel content. This effect persisted after a complete drug washout in the interrupted group. These responses were paralleled by increased pAMPK availability and by reduced expression of TXNIP messenger RNA in colonic enterocytes exposed to prolonged metformin treatment. Conclusion: Metformin causes a selective increase in colonic 18F-FDG uptake. This effect appears after a relatively long period of treatment and persists soon after drug washout. Accordingly, the increased bowel glucose metabolism reflects a biologic response to chronic metformin treatment characterized by increased levels of pAMPK and reduced levels of TXNIP.This publication has 25 references indexed in Scilit:
- AMP-Activated Protein Kinase (AMPK) Mediates Nutrient Regulation of Thioredoxin-Interacting Protein (TXNIP) in Pancreatic Beta-CellsPLOS ONE, 2011
- Increased F-18 FDG Intestinal Uptake in Diabetic Patients on MetforminClinical Nuclear Medicine, 2011
- Impact of Medication Discontinuation on Increased Intestinal FDG Accumulation in Diabetic Patients Treated With MetforminAmerican Journal of Roentgenology, 2010
- Clearance of the high intestinal 18F-FDG uptake associated with metformin after stopping the drugEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- High and typical 18F-FDG bowel uptake in patients treated with metforminEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- Role of AMP-activated protein kinase in mechanism of metformin actionJCI Insight, 2001
- Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestineBiochemical Pharmacology, 2000
- Effect of N-butylscopolamine on intestinal uptake of fluorine-18-fluorodeoxyglucose in PET imaging of the abdomenNuklearmedizin, 2000
- Elimination of Artifactual Accumulation of FDG in PET Imaging of Colorectal CancerClinical Nuclear Medicine, 1998
- Importance of the intestine as a site of metformin‐stimulated glucose utilizationBritish Journal of Pharmacology, 1994